NIPD Genetics is a leading innovative biotechnology company active in the field of developing, engineering and providing in vitro genetic testing solutions. NIPD Genetics was founded in 2010 to commercialize pioneering research work in the field of genetic testing. NIPD Genetics applies its proprietary genetic and bioinformatic analysis tools to develop novel tests and technologies for prognosis, prevention of genetic diseases, better clinical management and therapy. NIPD Genetics laboratories are accredited by CAP and certified by CLIA and ISO standards. We provide safe, accurate and reliable in vitro genetic testing services internationally.
Prof. Philippos Patsalis
Founder, Chief Executive Director & Chief Medical Officer
Distinguished Professor Philippos Patsalis is a world-class geneticist, researcher and successful business entrepreneur, who has been leading public and private sector organizations since 1993. Prof. Patsalis held numerous executive positions and he served on several international scientific and business Boards, Committees and Councils during his 25-year distinguished career. Most notably, he held the presidential-appointed position of Minister of Health of the Republic of Cyprus. During his tenure as a Health Minister and under austere IMF, European Central Bank and European Commission economic measures, Prof. Patsalis implemented major reforms on the national healthcare sector. Among others, he restructured the operations of pharmaceuticals, he initiated the autonomization of public hospitals, and he introduced a new healthcare system.
He is currently the CEO and CMO of NIPD Genetics Public Company, a company he founded and has been successfully leading since its inception in 2010. NIPD Genetics is an international biotechnology company and a key-player within the competitive non-invasive genetic diagnostics field. Its focus is on developing and providing to the international market innovative technologies and products and it has demonstrated substantial growth.
Earlier in his career, Prof. Patsalis was for 10 year the founder and director of both The Department of Cytogenetics and Genomics and Translational Genetics and for 8 years the Chief Executive Director of The Cyprus Institute of Neurology and Genetics, the largest and most technologically advanced research institute of Cyprus. During his leadership the Institute achieved tremendous growth and international recognition as a center of excellence. Prof. Patsalis was also the founder of the Akeso Fertility Center Company and the founder of The Cyprus School of Molecular Medicine, an academic school for graduate education for which he served as its first Professor, Provost and Chief Executive Director.
Prof. Patsalis is an accomplished executive director, researcher and entrepreneur who has been bestowed with more than 30 national and international awards and distinctions for his contribution to science, innovation and business. Namely, the US-State Alumni Award of USA State Department, the National Award for Contribution to Scientific Research by the President of the Republic of Cyprus, and The Silver Medal of the Parliament – the highest honor of distinction by the Parliament of the Republic of Cyprus. He filed multiple patents, contributed to over 10 books, has published more than 130 peer-reviewed scientific papers in prestigious Journals, and has been invited to lecture in over 200 institutions, universities and conferences. He obtained more than 40 competitive research grants for tens of millions, including the very prestigious ERC Advance Grant and raised tens of millions of capital investments from individual and investments funds. He currently also holds the title of Professor of Human Genetics of the University of Nicosia Medical School.
Prof. Patsalis is actively involved with Institutions, Councils and company Boards that play a significant role in shaping and structuring policies in public and private organizations. He is the President of the National Board for Research and Innovation (CY), an elected member of the Board of the European Society of Human Genetics (EU) and a Board member of MANA Products Ltd (USA) among others. Prof. Patsalis is an ardent proponent of responsible scientific and business progress and champions the advancement of research, innovation and entrepreneurship.
Prof. Philippos Patsalis received his BSc degree from the Aristotelian University of Salonica, Greece and his MA, MPh and PhD degrees from the City University of New York. He underwent specialization and post-doctoral training at Cornel Medical Center, New York University, Memorial Sloan Kettering Cancer Center and Columbia University. He is a Certified and Accredited Laboratory Director in Cytogenetics and Molecular Genetics by the New York Department of Health and by the College of American Pathologists. In addition, he is a Certified High Complexity Laboratory Director by the American Board of Bioanalysis.
Chief Scientific Officer
Dr. Koumbaris joined NIPD Genetics in 2011 as the Head of Research and Development and led the company’s R&D activities. He was appointed Chief Scientific Officer at NIPD Genetics in 2015 and oversees all scientific activities. He is an expert in Genomics, Transcriptomics and Epigenomics, Non-Invasive Diagnostics, and Advanced Genetic Technologies. He is also an inventor and author of numerous peer-reviewed papers published in international scientific journals. His research has been presented at various international scientific meetings. Dr. George Koumbaris received his BSc and MSc degrees from Florida State University and completed his PhD in Molecular Genetics at The Cyprus Institute of Neurology and Genetics where he also served for many years as a researcher in Genetics, Biotechnology and Non-Invasive Prenatal Diagnosis.
Chief Commercialization Officer
Dr. Nicolas Stephanou received his BSc in Biochemistry from SUNY Stony Brook, NY, his PhD in Immunology and Microbiology from Cornell University Weill Medical College and his MBA in Strategy from Cornell University Johnson Business School. He has an extensive knowledge and experience in Molecular Genetics as well as products commercialization. He has worked in the Pharmaceutical industry at key managerial positions acquiring extensive experience in product management, strategic marketing, product development and sales at a global level. His responsibilities involved the promotion of both prescription (Rx) pharmaceuticals and Over The Counter (OTC) medicines. In his latest role, he led a company specializing in international sales and marketing of Food Supplements and Medical Devices. Dr. Stephanou joined NIPD Genetics in 2016 as a Chief Commercialization Officer overseeing the sales expansion and global partnerships.
Chief Business Development Officer
Dr. Hari Radhakrishnan joined NIPD Genetics in 2015 to lead the marketing and business development efforts of NIPD Genetics. As Chief Business Development Officer, he is responsible for advising the CEO on business strategy, bringing the new products to market, marketing of the company’s product portfolio, training the company’s and partners’ sales teams, and managing the research and regulatory affairs offices. He also advises the research and development team in developing innovative bioinformatics software for various applications. He has extensive knowledge in the fields of high-performance computing and in business development. As an independent software consultant, he worked with several universities and agencies on the application of super computers to solve complex physics and engineering problems. He obtained his Bachelor of Engineering from IIT Roorkee, India; and PhD in Chemical Engineering from University of Minnesota, USA.
Chief Production and Information Technology Officer
Andreas Lambis joined NIPD Genetics in 2015. He specializes in business process automations and business driven development of information technology systems that satisfy the needs of the Technology Transfer platform customers and the company’s internal production and services. He has worked for many years in the private sector as a business consultant in the areas of software development and business integration. Andreas is a member of the PMI and has worked in many medium and large projects in the financial, banking, utilities, education, human resources and health services sectors for both private and public institutions in Europe and the Middle East. Andreas Lambis is an engneer by training, B.Sc. with honors and M.S. in Electrical Engineering from the Pennsylvania State University, with extensive experience in the information technology field.
Elena Sakkalou Rouva
Chief Financial Officer
Mrs Elena Sakkalou Rouva is a Certified Public Accountant. She holds an MBA from Baruch College, City University of New York and an MSc in Risk Management from New York University. Her professional career was mainly in the financial industry. She has extensive experience in the international business sector in Cyprus. Also, in banking, she worked in one of the biggest banks in Cyprus through various positions in internal audit, risk management and NPL management. The main focus of her work was on the credit portfolio of the bank and involved the analysis of financials, business plans, projections, budgets and corporate structures. She joined NIPD Genetics in December 2018 at the position of the Chief Financial Officer.
Chief Administrative Officer
Mrs. Mallouri develops and executes NIPD Genetics HR strategies and activities that foster growth, innovation, and organizational effectiveness. She leads the initiative, NIPD Genetics is an Employer of Choice, fostering a work culture that attracts and retains exceptional talent. Mrs. Mallouri joined the company in 2011 and she has more than 25 years of experience in administrative and HR services. Part of her date to date operations include, collaborating with key team members across departments to drive employee engagement, morale and performance and advising the executive team on organizational restructuring so as to create a more agile, cost-efficient workforce. She is also responsible for the negotiation of employees’ and consultants’ contracts and maintaining the company’s archives. Mrs. Mallouri administers the company’s archives and keeps registry of all intellectual property and signed agreements. Additionally, she is responsible for the administration of the Company’s Shareholders activities and keeping a record of the minutes of the Board of Directors. Mrs. Mallouri studied Business Administration and has an M.B.A. from Keele University in the United Kingdom.
Head of Research and Development
Dr. Ioannides joined NIPD Genetics in 2015 and is currently the Head of R & D overseeing product development, technology optimization and all research activities of the company. He served for many years as a molecular cytogeneticist, a researcher, and later as acting head of the Translational Gentetics Team at the Cyprus Institute of Neurology and Genetics.He has extensive theoretical and technical knowledge of molecular techniques such as digital PCR and Next Generation Sequencing, as well as of development of clinical tests and clinical diagnostics. He is an expert in genomics, epigenetics and non-invasive diagnostics. He has published several peer-reviewed articles and his research has been presented at various national and international scientific conferences. Dr. Marios Ioannides received his BSc and Msc in Microbiology from the University of South Florida, and his PhD in Medical Genetics from the University of Cyprus and the Cyprus Institute of Neurology and Genetics.
Head of Clinical Services
Dr Kypri joined NIPD Genetics in 2011 and is currently the Head of laboratory operations overseeing all laboratory activities related to the provision of services. She received numerous awards and fellowships and has a broad research background including more than 10 years in molecular and cell biology techniques. She has published several peer-reviewed articles and her research has been presented at various national and international scientific conferences. Dr. Elena Kypri received her Bsc in Clinical Laboratory Science from the University of Arizona and her PhD degree in Molecular Genetics and Microbiology from the University of Texas at Austin. She is also board certified by the American Society of Clinical Pathologists. She underwent specialization and post-doctoral training from the Department of Biological Sciences at University of Cyprus and the Institute of Molecular Biology and Biotechnology in Crete.
Board of Directors
DR. Nicos Michaelas
Dr Nicos Michaelas is the Managing Director of Demetra Investments Public Ltd, the largest investment company listed on the Cyprus Stock Exchange. He oversees the operations and the investment portfolio of the company and manages investments across multiple asset classes including capital markets, real estate and private equity. Dr Michaelas is also as Member of the Board of Directors of Logicom Public Ltd, a global IT distribution and services company. Nicos holds a BA(Hons) in Industrial Economics from the University of Nottingham in the UK and a Ph.D. in Financial Economics from Manchester Business School. In his early career he worked as an academic in the UK, researching/teaching business economics and financial management at Manchester Business School. Since the year 2000 he has been working in the investment management industry.
Constantine Iordanou has been Chairman of the Board of ACGL since November 2009 and was Chief Executive Officer of ACGL from August 2003 to March 2018. From March 1992 through December 2001, Mr. Iordanou served in various capacities for Zurich Financial Services and its affiliates, including as Senior Executive Vice President of group operations and business development of Zurich Financial Services, President of Zurich-American Specialties Division, Chief Operating Officer and Chief Executive Officer of Zurich-American and Chief Executive Officer of Zurich North America. Prior to joining Zurich, he served as President of the commercial casualty division of the Berkshire Hathaway Group and served as Senior Vice President with the American Home Insurance Company, a member of the American International Group. Since 2001, Mr. Iordanou has served as a director of Verisk Analytics, Inc. (formerly known as ISO Inc.). He holds an aerospace engineering degree from New York University.
Prof. Philippos Patsalis
Prof. Philippos Patsalis obtained his BSc in Biology from the Aristotelian University of Salonica, Greece and his MA, MPh and PhD in Genetics from the City University of New York, USA. He underwent specialization and post-doctoral training at Institute Pasteur, France, Cornell Medical Center, New York University, Memorial-Sloan Kettering Cancer Center and Columbia University, in New York, USA. He also received professional certification and licensing to practice as a Laboratory Director in the specialties of Cytogenetics and Molecular Genetics from the New York Department of Health, USA and Accreditation as Laboratory Director in Cytogenetics and Molecular Genetics from College of American Pathologists, USA.
Prof Patsalis worked as Director and Founder of the Department of Cytogenetics and Genomics and the Translational Genetics Team at the Cyprus Institute of Neurology and Genetics; Founder and Chief Executive Director of the biotechnology company NIPD Genetics; Founder, Professor and Provost of the Cyprus School of Molecular Medicine; Chief Executive Medical Director of the Cyprus Institute of Neurology and Genetics and Minister of Health of the Republic of Cyprus. As of November 2015 he holds the position of Distinguished Professor at the Cyprus Institute of Neurology and Genetics and the Cyprus School of Molecular Medicine and the position of Chief Executive Director of NIPD Genetics. He is also an Honorary Professor of St. George’s University of London/Medical School at the University of Nicosia, Adjunct Professor at the University of Cyprus/Department of Biology and Visiting Professor at the University of Ioannina/Medical School. As of 2010, he serves as Founder and CEO of NIPD Genetics until today, excepting the period that he served as Minister of Health.
Prof. Patsalis is a scientist with international recognition in the field of Human Genetics. He has been invited as lecturer to more than 200 Universities and international conferences. He has competitively obtained more than 40 research grants and funding of over 20 million euro from international organizations such as the 5th, 6th, 7th European Framework Programs and the most prestigious grant in the European Union known as the ERC Advanced Grant, which is based purely on excellence. He was appointed to several Editorial Boards of scientific journals and has filed several patents. He contributed chapters in 10 books and published more than 130 peer-reviewed scientific publications in international journals, such as Nature Medicine, Lancet, Human Molecular Genetics, American Journal Human Genetics, etc. In Cyprus, he is the President of the National Council of Research, Innovation and Entrepreneurship and has served on several other Boards, Committees and Councils. In Europe, he is the national representative of Cyprus in many European committees and councils, as well as elected Boards of Directors such as the European Society of Human Genetics, the European Cytogenetics Association, etc. He has been appointed as external member of National Academies of Sciences and has been honored with many national and international awards, including the Cyprus National Research Award, the Cyprus National Innovation Award, the Most Notable Scientific and Social Contribution Award University of Nicosia, the US State Alumni Award-State Department USA, the Silver Medal of the Parliament which is the highest honorary distinction of the Parliament of the Republic of Cyprus and the National Award from the President of the Republic of Cyprus.
Mr. Alexis Charalambides has completed his studies in economics at the University of Leicester in 1990 when he was firstly involved in the family business, Charalambides Dairies Limited. In 2008, Vivartia (Cyprus) Limited was formed from the merger of Charalambides Dairies and Christis Dairies and in 2011 Charalambides Christis Ltd was formed by the acquisition of the company by Mr. Alexis Charalambides and Mr. Menelaos Shiacolas families. Charalambides Christis is the largest and longest-running dairy industry in Cyprus. It remains a leader in the food production and distribution sector, timelessly providing, and always in accordance with international standards of quality and know-how, products of high nutritional value and quality, while preserving the authenticity of flavours. It is one of the most powerful industries in the country and is also distinguished for its Corporate Social Responsibility, with the active giving and social solidarity programme “SYMMETOCHI”, embracing the whole of Cyprus, and providing thousands of smiles to children’s faces. The quality of Charalambides Christis is internationally recognised with the company being active in more than 40 countries, making it the largest export company in Cyprus. Mr. Charalambides is the Executive Chairman of the Board of Directors of Charalambides Christis Ltd since 2011. Additionally, he is a member of the Board of Directors of the Cyprus Employers & Industrialists Federation and a member of the Industrial Committee of the Nicosia Chamber of Commerce and Industry. He is also a member of the Board of Directors of the Cyprus Institute of Neurology & Genetics and the Vice President of the Nicosia Race Club which he has served as the President in 2007 and 2008, and an elected member of the Board since 2004.
Georgios Kallenos is from Dhali, Nicosia and he is married with 3 children. He attended the Pancyprian Gymnasium of Nicosia and after the completion of his national duty he went for studies in New York, United States. He is a graduate from St. John’s University of New York where he has earned a BSc in Economics. From the same University he has earned with scholarship the Master of Business Administration (MBA). While he was studying in New York he worked in the construction market (Aluminum siding) where he eventually founded a small construction company taking sub construction contracts from bigger construction companies. At the same time he was working as a Church manager and Greek school teacher at the Greek Orthodox Church of Resurrection in Clen Cove Long Island. Georgios Kallenos has more than 25 years experience in the areas of Information Technology, Property Development and Investments. He is the founder and the Managing director of the following companies:
G. Kallenos Infosystems Ltd which specializes in the area of customized Software applications and computer networks,
G. Kallenos Developers Ltd specializes in the planning & development of residential and commercial building projects, and GAPILK Investments Ltd which participates in the share capitals of various innovating companies such as the NIPD Genetics.
He has served as a member of the board of directors of the Cyprus Institute of Neurology and Genetics (CING) from 2014 – 2018.
Georgios serves as president of the AHEPA Cyprus CY004 “Photos Photiades” Idalion chapter.
DR. NEARCHOS IOANNOU
Dr. Ioannou was born in Limassol in 1958. He studied political economics at the University of West Berlin and was a lecturer at the Institute of Sociology at Free University Berlin. He holds a Ph.D and from 1984 to 1990 he worked at Dresdner Bank AG in Germany. He then worked at the Bank of Cyprus until 2006. From 2006 to 2017 he was the General Manager of the Limassol Cooperative Savings Bank, while from February 2017 until August 2018 he was the Director of the International Affairs Department of the Cooperative Cyprus Bank. Since 2016 he has been working as a lecturer at the Cyprus University of Technology (TEPAK) in the field of finance. Since 8/2020 he is the Managing Director of Demetra Holdings plc. He has been a member of several Boards of Directors and since 2019 he has been a member of the Board of Directors of Lordos Hotels (Holdings) Public Ltd., Golden Coast Ltd (Chairman) and NIPD Genetics. In addition, he writes books and plays.
Prof. Suresh Jhanwar has forty years of clinical and research experience in Cancer Genomics and Molecular Medicine and he is recognized as a world renowned scientist in the field of Cancer Genetics. He served as the Director of the Cytogenetics Laboratory at the Memorial Sloan Kettering Cancer Center’s (MSKCC) from 1996 to 2013. His laboratory was the first one to be designated as the “Laboratory of Solid Tumor Genetics” in 1988, at the Department of Pathology of Memorial Sloan Kettering Cancer Center. In 2015, he was appointed as a Member Emeritus at the MSKCC. He has received many international honors and awards and he has professional certification and licensing in Cancer Cytogenetics, Molecular Oncology and Predisposition Cancer Genetics specialties, from the New York Department of Health, USA. He also served as a key member of various disease management teams and actively participated in various clinical trials for both hematologic as well as solid tumors. Prof. Jhanwar was recently elected as a Foreign Fellow of the oldest Academy of Sciences in India, which in the past 30 years elected only 84 such fellows internationally. He also served as Professor of Pathology in the Department of Pathology and Laboratory Medicine of Weill Cornell Medical College. Prof. Jhanwar also serves as a member of the editorial boards of several journals including Anticancer Research, International Journal of Human Genetics, and Cancer Genomics and Proteomics. He has published in high impact journals like PNAS, Science, Nature, Nature Genetics, NEJM, Blood, Oncogene, MCB, Cancer Research, Cell and EMBO, among others, resulting in more than 225 publications.
Prof Joris Vermeesch was born in Belgium in 1965. He obtained his BSc degree from the Bioengineer University of Gent, Belgium and his PhD degree in Chemistry and Biotechnology from the University of Nebraska, USA. He is the Head of the Cytogenetics unit of the CME-UZ research group since 2001 and the Coordinator of Genomics Core since 2008. Furthermore, as from 2008, Prof. Vermeesch has been elected as the President of the Belgian Society of Human Genetics. He also serves as member of the Board of Directors of several organizations such as the International Standards on Array CGH Consortium (ISCA), the European Cytogenetics external Quality Control and the International Society of Prenatal Diagnosis. He is the founder of a biotech spin-off company known as “Cartagenia”. Prof. Vermeesch is a scientist with international reputation in the provision of cytogenetics, genomics, genetics, single cell, preimplantation, prenatal and postnatal diagnosis. He has published more than 130 peer review papers in scientific journals including Nature, J Med Genet, Am J Hum Genet, Nucleic Acid research, etc. He has collaborated with Prof. Patsalis in several research projects in the last ten years with great success.
Dr. Voula Velissariou received her BSc degree from the Department of Biology, University of Athens, Greece and her PhD in Genetics from the Department of Genetics, University of Cambridge, UK. She underwent specialization training in cytogenetic prenatal diagnosis methods and CVS culture techniques from the Department of Medical Genetics, Churchill Hospital, Oxford, UK. Dr Velissariou has also obtained training in molecular cytogenetic methodologies from Guy’s Hospital, London and University College London, London. Dr Velissariou is the Head of the Cytogenetics and Molecular Genetics Department in Bioatriki SA in Athens, Greece since January 2016. She has served as founder member of the Panhellenic Association of Medical Geneticists as well as member of the board of Panhellenic Union of Biologists. She is a scientist with an international reputation in the provision of prenatal and postnatal genetic diagnostic services in Greece with 30 years’ experience.
Assoc. professor Jūratė Kasnauskiene from Lithuania joined NIPD team in 2016 for scientific and clinical collaboration. She has a MD and PhD in Clinical Genetics at Vilnius University, more than 20 years professional experience in molecular genetic testing, clinical counseling and teaching (she is assoc. professor of Vilnius University) and currently works as a Head of department of Molecular Diagnostic at Klaipeda University Hospital. Jurate is a member European and Lithuanian Society of Human Genetics as well as a board member of Lithuanian Society of Laboratory Medicine. She has participated and leaded numerous Lithuanian and European scientific and healthcare projects and has worked in committees of Lithuanian Ministry of Health. Jurate has published a number of international publications and has taken trainings in Germany, Netherlands, Taiwan, Spain, Cyprus, UK. Jurate’s fields of interest include cancer genetics and prenatal genetics as well as infertility genetics and intellectual disabilities genetics.